GLP-1受体激动剂在心脏移植后糖尿病管理中的疗效与安全性：来自西班牙多中心研究的启示
Posted inCardiology Clinical Updates Diabetes & Endocrinology

Efficacy and Safety of GLP-1 Receptor Agonists in Managing Post-Transplant Diabetes Among Heart Transplant Patients: Insights from a Multicenter Spanish Study

This multicenter retrospective study shows that GLP-1 receptor agonists improve glycemic control and cardiometabolic parameters with good tolerance in heart transplant recipients with type 2 diabetes, supporting their therapeutic role in this high-risk population.
持续葡萄糖监测助力未用胰岛素2型糖尿病血糖管理：CONNECT试验带来新证据
Posted inDiabetes & Endocrinology Internal Medicine news

Enhancing Glycemic Control in Non-Insulin-Treated Type 2 Diabetes with Continuous Glucose Monitoring: New Evidence from the CONNECT Trial

The CONNECT trial demonstrates that continuous glucose monitoring (CGM) significantly improves glycemic control in adults with non-insulin-treated type 2 diabetes managed in primary care, reducing HbA1c levels and hyperglycemia risk without increasing hypoglycemia.
Orforglipron 在 2 型糖尿病中的心血管安全性和治疗潜力：来自 ACHIEVE-4 3 期试验的发现
Posted inClinical Updates Diabetes & Endocrinology news

Cardiovascular Safety and Therapeutic Potential of Orforglipron Versus Insulin Glargine in Type 2 Diabetes with Elevated Cardiovascular Risk: Insights from the ACHIEVE-4 Phase 3 Trial

A comprehensive review of the ACHIEVE-4 trial confirms orforglipron's cardiovascular safety non-inferior to insulin glargine in type 2 diabetes patients at elevated cardiovascular risk, highlighting its oral administration and safety profile advantages.
Efficacy and Safety of the twiist Automated Insulin Delivery System in Insulin-Treated Type 2 Diabetes: A Comprehensive Review of the twiist-T2D Pivotal Trial and Related Evidence
Posted inClinical Updates Diabetes & Endocrinology news

Efficacy and Safety of the twiist Automated Insulin Delivery System in Insulin-Treated Type 2 Diabetes: A Comprehensive Review of the twiist-T2D Pivotal Trial and Related Evidence

The twiist AID system significantly improves glycemic control and patient satisfaction in insulin-treated type 2 diabetes over 13 weeks, demonstrating safety and effectiveness supported by complementary real-world and RCT data.
Evaluating the Safety of GLP-1 Receptor Agonists and New-Generation Glucose-Lowering Agents in Pregnant Women with Type 2 Diabetes: Insights from a French Nationwide Study
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Evaluating the Safety of GLP-1 Receptor Agonists and New-Generation Glucose-Lowering Agents in Pregnant Women with Type 2 Diabetes: Insights from a French Nationwide Study

A French nationwide cohort study finds first-trimester exposure to second-line glucose-lowering agents, including GLP-1 receptor agonists, is generally safe for pregnancies with type 2 diabetes, though a slight increase in cardiac malformations cannot be excluded.